Last updated on October 2006

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.


Brief description of study

The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.

Detailed Study Description

- To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. - To determine the 2 and 3 year rate of locoregional disease control. - To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed by 12 weeks of complementary treatment with cetuximab. Both acute and chronic toxicity will be assessed. - To determine specific disease-free survival, event-free survival, disease-specific survival and overall survival - To determine acute and late toxicity - To determine EGFR, p53, Ki67, and evaluate its value as a prognostic factor.

Clinical Study Identifier: NCT00251381

Contact Investigators or Research Sites near you

Start Over

Alicia Lozano, MD

Institut Catala Oncologia: Hospital Duran y Reynals
Hospitalet de Llobregat, Spain
  Connect »

Palmira Foro, MD

H. del Mar / H. de la Esperanza
Barcelona, Spain
3.79miles
  Connect »

Manuel De Vega, MD

H. de la Santa Creu I Sant Pau
Barcelona, Spain
4.09miles
  Connect »

Antonio Arellano, MD

Hospital Germans Tries i Pujol
Badalona, Spain
4.74miles
  Connect »